Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 5Phase 1 3Phase 4 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 8Sarcoma 3Gastrointestinal 3Tumor-Agnostic 2Lymphoid 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Gastrointestinal Stromal Tumors 2Neoplasms 1Chordoma 1

Interventions

Temozolomide 62Cyclophosphamide 59Radiotherapy 47Doxorubicin 36Filgrastim 26Irinotecan 24Radiation 23Gemcitabine 23fludarabine 22Magnetic Resonance Spectroscopy 20Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × nilotinib × Sarcoma × Clear all
NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Massachusetts General Hospital

Phase 1 Completed
23 enrolled
Sarcoma

Chordoma

NCT00135005 2020-12-08

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Novartis

Phase 1 Completed
59 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Novartis

Phase 1 Completed
14 enrolled
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡